Iovance Biotherapeutics reported third quarter 2026 revenue of US$121.47 million and a net loss of US$22.27 million, reaffirmed full year 2026 revenue guidance of US$410 million to US$420 million, and...
Source LinkIovance Biotherapeutics reported third quarter 2026 revenue of US$121.47 million and a net loss of US$22.27 million, reaffirmed full year 2026 revenue guidance of US$410 million to US$420 million, and...
Source Link
Comments